There is no single ICD-10 code for a GLP-1 prescription. The code describes the documented condition or medication-use status. Start with the reason for treatment, then check the exact product and payer requirement.
Diagnosis examples link to the April 1–September 30, 2026 code set. Use the service-date release for other dates. Indication summaries below are selected documentation context, not the complete label or a coverage determination.
Semaglutide · GLP-1 receptor agonist
Ozempic: start with the documented diabetes condition
The May 2026 prescribing information, section 1 includes glycemic control in adults with type 2 diabetes, plus cardiovascular and kidney-risk indications in specified adults with type 2 diabetes. The presence of this prescription alone does not establish a particular complication.
Code distinction: E11.9 and E11.65 describe different documented conditions. If the request concerns kidney disease, review E11.22 and its additional-stage instruction alongside the CKD stage reference. The documented condition, not the drug name, determines the code.
Tirzepatide · GIP/GLP-1 receptor agonist
Mounjaro: verify the indication named in the request
The August 2026 prescribing information, section 1 includes glycemic control in adults and children aged ten years and older with type 2 diabetes, and cardiovascular risk reduction in adults with type 2 diabetes at high risk for those events.
Code distinction: the diabetes reference separates the condition from therapy status. Mounjaro and Zepbound contain tirzepatide, but their labels and the payer’s documentation requests must be checked separately.
Semaglutide · GLP-1 receptor agonist
Wegovy: keep the formulation and reason for treatment together
The current prescribing information, section 1; checked September 15, 2026 distinguishes injection and tablets. It includes weight-management and cardiovascular indications with specified populations; the injection also has a MASH indication with its own conditions. Use the full label for the exact formulation and population.
Code distinction: when obesity is the documented condition, review the E66 diagnosis and BMI notes. The adult BMI entries are separate from the diagnosis. For documented MASH, K75.81 retains the NASH description and includes MASH; a code alone does not establish the label’s other conditions. The manufacturer’s PA guide directs users to confirm the payer’s required documentation.
Tirzepatide · GIP/GLP-1 receptor agonist
Zepbound: distinguish weight management from sleep-apnea documentation
The August 2026 prescribing information, section 1 includes weight reduction and long-term maintenance for specified adults with obesity or overweight, and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
Code distinction: G47.33 describes obstructive sleep apnea; the code alone does not state severity. Keep it distinct from the documented obesity diagnosis and BMI detail. Ask for the documented condition and the supporting information specified by the plan. Lilly links its PA guide and coverage support from its professional resource page.
Is there a long-term-use ICD-10 code for these drugs?
Z79.85 describes long-term use of injectable non-insulin antidiabetic drugs. It is a therapy-status code, not an Ozempic, Mounjaro, Wegovy or Zepbound diagnosis code. The CDC tabular list and official diabetes coding guidelines define its role. Do not automatically apply it to every GLP-1 prescription, every indication or an oral formulation.
For searches such as “long-term use of Zepbound ICD-10,” first establish which documentation field is being requested: the treated condition, medication-use status or an adverse event. These are different coding questions. Adverse-effect, poisoning and underdosing coding require their own clinical facts and code instructions; this guide does not supply a brand-based shortcut.
A useful handoff when the PA is missing information
The Wegovy PA resource names incomplete information, diagnosis-code problems and benefit exclusions among possible denial reasons. The next step depends on the actual response.
- Keep the exact request. Record the drug, formulation, plan, returned message and the field the payer is asking to clarify.
- Locate the documented condition. Ask the prescriber for missing diagnosis details and the records the plan requests. Do not replace the diagnosis with a different one to seek coverage.
- Open the governing policy. Use the formulary directory and payer documents. Match the effective date and benefit; a public list is not a member-specific answer.
- Separate the remaining issues. A completed diagnosis field does not resolve a benefit exclusion, quantity limit or missing authorization. Keep the payer’s next instruction with the request.
This is a documentation-organizing checklist. It does not prescribe a universal PA submission process or infer which records a particular payer requires.
Diagnosis code, product identifier or reject code?
- ICD-10-CM
- Describes the documented condition, encounter or status. Use the selected code reference and CDC’s full classification.
- NDC
- Identifies a drug product/package. Use the FDA NDC Directory or DailyMed; this guide does not maintain package data.
- Claim reject
- Identifies the returned claim issue. Open 39: diagnosis field, 75: PA required or the full reject lookup.
Sources11 linked sources
- CDC releases and service dates
- CDC April 2026 tabular list
- FY2026 official coding guidelines
- Ozempic prescribing information · May 2026
- Mounjaro prescribing information · August 2026
- Wegovy prescribing information · checked September 15, 2026
- Zepbound prescribing information · August 2026
- Wegovy prior-authorization resource
- Zepbound professional resources
- FDA NDC Directory
- DailyMed